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Abstract
Radical cystectomy for muscle-invasive bladder cancer (MIBC) patients frequently impairs their quality of life (QOL) due to
urinary diversion. To improve their QOL, a bladder-sparing alternative strategy using chemoradiation has been developed.
In bladder-sparing protocols, complete response (CR) to induction chemoradiation is a prerequisite for bladder preservation
and favorable survival. Thus predicting chemoradiation resistance and overcoming it would increase individual MIBC
patients’ chances of bladder preservation. The aim of this study is to investigate putative molecular targets for treatment
aimed at improving chemoradiation response. Expression levels of erbB2, NFkB, p53, and survivin were evaluated
immunohistochemically in pretreatment biopsy samples from 35 MIBC patients in whom chemoradiation sensitivity had
been pathologically evaluated in cystectomy specimens, and associations of these expression levels with chemoradiation
sensitivity and cancer-specific survival (CSS) were investigated. Of the 35 patients, 11 (31%) achieved pathological CR, while
tumors in the remaining 24 patients (69%) were chemoradiation-resistant. Multivariate analysis identified erbB2 and NFkB
overexpression and hydronephrosis as significant and independent risk factors for chemoradiation resistance with
respective relative risks of 11.8 (P=0.014), 15.4 (P=0.024) and 14.3 (P=0.038). The chemoradiation resistance rate was
88.5% for tumors overexpressing erbB2 and/or NFkB, but only 11.1% for those negative for both (P ,0.0001). The 5-year
CSS rate was 74% overall. Through multivariate analysis, overexpression of erbB2 and/or NFkB was identified as an
independent risk factor for bladder cancer death with marginal significance (hazard ratio 21.5, P=0.056) along with
chemoradiation resistance (P=0.003) and hydronephrosis (P=0.018). The 5-year CSS rate for the 11 patients achieving
pathological CR was 100%, while that for the 24 with chemoradiation-resistant disease was 61% (P=0.018). Thus, erbB2 and
NFkB overexpression are relevant to chemoradiation resistance and are putative targets aimed at overcoming
chemoradiation resistance in MIBC.
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Introduction
Bladder cancer is the 5
th most common cancer in the US, with
70,530 new patients and 14,680 deaths recorded in 2010 [1].
Muscle-invasive bladder cancer (MIBC) accounts for one-third of
all bladder cancer cases [2]. Radical cystectomy is the reference
standard of care for patients with MIBC, but urinary diversion,
which must be performed concurrently with radical cystectomy,
and postsurgical morbidity potentially compromise patients’
quality of life. To overcome these issues, bladder-sparing ap-
proaches with various modalities have been investigated. Among
them, trimodality protocols consisting of transurethral resection
(TUR), chemotherapy, and radiotherapy have yielded the most
favorable oncological outcomes, with 5-year overall survival rates
of 50 to 60%, which are comparable to contemporary survival
rates of immediate radical cystectomy series [3,4]. In most
chemoradiotherapy (CRT)-based bladder-sparing protocols, pa-
tients who achieve complete response (CR) after induction CRT
are selectively subjected to consolidative therapies for bladder
preservation, whereas those who do not achieve CR are
recommended to undergo radical cystectomy [5]. In addition,
the response to induction CRT has a strong impact on the survival
of MIBC patients regardless of subsequent radical cystectomy with
curative intent [6,7]. Thus, the ability to predict non-CR patients
and the development of a novel strategy to improve their response
to CRT would increase the chances of bladder preservation and
potentially improve survival outcomes in MIBC patients.
A number of translational studies have been conducted to
identify molecular markers that predict therapeutic response to
chemotherapy and/or radiotherapy in patients with MIBC or
more advanced forms of the disease. Several molecules and genetic
modifications have been identified as predictors of CRT response
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predicting CRT response without also specifically attempting to
improve CRT response by targeting the molecules responsible for
CRT resistance.
The aim of the current study is to identify putative molecular
targets to improve CRT sensitivity and thereby to improve patient
prognosis. Of several molecular markers reportedly predict-
ing unfavorable tumor response to CRT or radiotherapy
[8,13,14,15,16,17,18,19,20], those that can be targeted by small
molecules or monoclonal antibodies include erythroblastic leuke-
mia viral oncogene homolog 2 (erbB2, also known as HER2/neu)
[8], nuclear factor-kB (NFkB) [13,14], mutant p53 [17,18], and
survivin [19]. We investigated associations of the expression
profiles of these oncoproteins with both CRT sensitivity and
cancer-specific survival (CSS) in a cohort of MIBC patients in
whom CRT sensitivity of tumors had been pathologically
evaluated in cystectomy specimens.
Methods
Ethical statement
The ethical committee of Tokyo Medical and Dental University
reviewed and approved the current study protocol (approval
number 602). Written informed consent was obtained from all
patients whose tumor tissues were examined for expression of
CRT resistance-associated proteins.
Patients
Between 1997 and 2008, 162 MIBC patients without clinical
metastasis were treated in accordance with our institutional
therapeutic protocol, which is described elsewhere [7,21,22].
Briefly, patients underwent transurethral resection (TUR) of
bladder tumor and induction CRT consisting of external beam
radiotherapy to the small pelvis (40 Gy) and two cycles of
concurrent intravenous cisplatin (20 mg/day for 5 days) separated
by a three-week interval. When bladder cancer was intravesically
localized and did not involve the bladder neck and trigone, and
residual disease was clinically absent or present only in a small
quantity after induction CRT, the patient could selectively
undergo consolidative partial cystectomy with pelvic lymph node
dissection for bladder preservation; otherwise radical cystectomy
was recommended. Of the 162 patients, 88 who underwent visibly
complete TUR before CRT and another 39 who did not undergo
cystectomy were excluded. In the remaining 35 patients in whom
tumor sensitivity to CRT was assessed pathologically in cystectomy
specimens, we investigated clinical and molecular variables
relevant to CRT resistance, which was defined as the presence
of pathological residual disease (non-CR) in cystectomy specimens.
TNM stage
Clinical stage was determined according to the 2002 TNM
system [23] based on findings obtained through TUR, bimanual
examination and CT of the chest, abdomen and pelvis. MRI of the
pelvis was also included starting in 2007.
Follow-up
Patients were followed essentially at 3-month intervals for the
first 2 years, at 6-month intervals for the following 3 years, and
yearly thereafter. Evaluations consisted of medical history, physical
examination, complete blood counts and blood chemistry, and CT
of the chest, abdomen and pelvis. Urine cytology, cystoscopy and
pelvic MRI were added for bladder-spared patients. Survival
intervals were calculated from the first day of CRT to the date of
death.
Immunohistochemistry
Immunostaining was performed as previously described [24]
using formalin-fixed paraffin-embedded tumor tissues obtained at
TUR before induction CRT. Primary antibodies used were pre-
diluted rabbit polyclonal anti-erbB2 antibody (Dako Cytomation,
Glostrup, Denmark; at 1:300), rabbit monoclonal antibody against
survivin (Cell Signaling Technology, Danvers, MA, USA; at
1:200), mouse monoclonal antibody against p53 (Pab1801; at 1:40)
and NFkB p65 (F-6; Santa Cruz Biotechnology, Santa Cruz, CA,
USA; at 1:100). Percentages of tumor cells positive for immuno-
staining were scored. Since NFkB p65 exerts its oncogenic
properties as a nuclear transcription factor, nuclear immunoreac-
tivity was evaluated as positive. The slides were reviewed at a
magnification of 6200 by two independent observers (Y.S. and
J.K.) who were blinded to clinicopathological data. In cases of
observer disagreement, a final decision was made by consensus
between the two observers.
Statistical Analysis
Differences between groups were assessed using the Chi-square
test for categorical data. Cut-off values of continuous variables best
predicting CRT resistance were determined by partition analysis.
Risk factors for CRT resistance and bladder cancer death were
evaluated using logistic regression analysis and the Cox propor-
tional hazard model, respectively. In multivariate analysis,
variables were selected using the backward stepwise method.
Survival curves were plotted using the Kaplan-Meier method and
their differences were assessed by log-rank test. These statistical
analyses were performed using JMP 8.0 statistical software (SAS
Institute, Cary, NC, USA). Differences were considered significant
at P ,0.05.
Results
Baseline statistics of the 35 eligible patients are listed in Table 1.
All MIBCs comprised high-grade urothelial carcinomas. Four
(11%) underwent partial cystectomy as consolidative therapy for
bladder preservation while 31 (89%) underwent radical cystecto-
my. Of the 35 patients, 11 (31%) achieved pathological CR; of the
remaining 24 patients with CRT-resistant MIBC, pathological T
stages were Tis in 2 (6%), T1 in 8 (23%), T2 in 4 (11%), T3 in 9
(26%), and T4a in 1 (3%). Pathological lymph node metastasis was
found in 3 patients (9%).
Immunoreactivity for erbB2, NFkB, p53, and survivin was
observed in 20 (57%), 16 (46%), 25 (71%), and 28 patients (80%),
respectively (Figure 1). The cut-off value of immunoreactivity that
best predicted clinical CRT resistance was 20% for erbB2, NFkB,
and survivin. For p53, a previously reported cut-off value of 10%
was used [25].
Among the clinical and molecular variables listed in Table 1,
univariate analysis revealed that erbB2 overexpression was
significantly associated with CRT resistance (P=0.003, Table 2);
NFkB overexpression, the presence of hydronephrosis, and tumor
size $5 cm were also associated with CRT resistance despite not
reaching statistical significance (P=0.055, 0.056, and 0.075,
respectively). Multivariate analysis identified erbB2 and NFkB
overexpression and the presence of hydronephrosis as significant
and independent risk factors for CRT resistance, with respective
relative risks of 11.8 (P=0.014), 15.4 (P=0.024) and 14.3
(P=0.038, Table 2). Neither p53 nor survivin was significantly
associated with CRT resistance. Ability to predict CRT resistance
was strengthened when data on the expression of both erbB2 and
NFkB were used; the CRT resistance rate was 88.5% among
tumors overexpressing erbB2 and/or NFkB but only 11.1%
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NFkB overexpression are relevant to CRT resistance in MIBC.
During the follow-up period (median 60 months, range 19-104),
10 patients died of bladder cancer. The 5-year CSS rate was 74%.
Clinicopathological and molecular variables associated with
bladder cancer death are listed in Table 3. Univariate analysis
revealed that CRT resistance and the presence of hydronephrosis
were significantly associated with bladder cancer death (P=0.003
and 0.008, respectively). Multivariate analysis revealed that CRT
resistance was the strongest and most independent risk factor
(P=0.003) followed by the presence of hydronephrosis (P=0.018).
Overexpression of ErbB2 and/or NFkB was also identified as an
independent risk factor for bladder cancer death with marginal
statistical significance (P=0.056). The 5-year CSS rate among the
11 patients with pathological CR was 100%, while that for the
remaining 24 with CRT-resistant MIBC was 61% (P=0.018).
Thus high sensitivity to CRT is associated with excellent survival
outcomes among MIBC patients.
Discussion
The current study showed that erbB2 and NFkB overexpression
play a potential role in CRT resistance and are independently
associated with unfavorable CSS with marginal significance in
MIBC patients treated with induction CRT plus cystectomy. This
indicates that erbB2 and NFkB are putative therapeutic targets for
treatments aimed at improving CRT sensitivity in MIBC. This is
the first study to demonstrate the relationship between NFkB
overexpression and CRT resistance in MIBC and the potential
prognostic impact of a combined expression profile of erbB2 and
NFkB in patients treated with induction CRT and cystectomy. As
we and others have demonstrated, a better response to CRT is
associated with more favorable survival outcomes [4,7,26]. Thus,
enhancing CRT sensitivity by targeting erbB2 and NFkB may
improve survival times among patients treated with CRT.
ErbB2 is a member of the epidermal growth factor receptor
(EGFR) family of receptor tyrosine kinases, which generate a
complex program of signal transduction events that modulates cell
proliferation, differentiation, invasion, and survival [27]. Unlike
EGFR, erbB2 does not have its own ligand; instead, it hetero-
dimerizes with other activated EGFR members to enhance and
prolong their signaling. In cancer cells overexpressing erbB2 due to
gene amplification, high basal autophosphorylation of erbB2
promotes oncogenic activities including metastasis and therapeutic
resistance [27]. According to previous reports on MIBC, erbB2
overexpression is an independent risk factor for cancer death in
patients undergoing radical cystectomy [28] and an independent
predictor of non-CR after CRT but not a risk factor for cancer
death in patients treated with CRT [8]. The results of our study are
consistent with those of the latter study, theoretically supporting the
adjunctive use of erbB2 inhibitors to improve CRT sensitivity.
Table 1. Baseline statistics of the 35 MIBC patients who
underwent induction CRT followed by cystectomy.
Variables No. of patients (%)
Gender
Female 15 (43)
Male 20 (57)
Median (range) age, years 71 (45-83)
Clinical T stage
T2 14 (40)
T3 18 (51)
T4a 3 (9)
Tumor size
,5 cm 17 (49)
$5 cm 18 (51)
Multifocality
No 12 (34)
Yes 23 (66)
Presence of CIS
No 28 (80)
Yes 7 (20)
Presence of hydronephrosis
No 23 (66)
Yes 12 (34)
Pathological T stage of cystectomy specimens
T0 11 (31)
Tis/1/2 2 (6)/8 (23)/4 (11)
T3/4a 9 (26)/1 (3)
Pathological N stage
N0 32 (91)
N1/2 2 (6)/1 (3)
ErbB2
Negative (,20%) 15 (43)
Positive ($20%) 20 (57)
NFkB
Negative (,20%) 23 (66)
Positive ($20%) 12 (34)
p53
Negative (,10%) 10 (29)
Positive ($10%) 25 (71)
Survivin
Negative (,20%) 7 (20)
Positive ($20%) 28 (80)
doi:10.1371/journal.pone.0027616.t001
Figure 1. Representative microphotographs of MIBC positive
for erbB2 (upper left), NFkB (upper right), p53 (lower left), and
survivin (lower right). Reduced from 6400.
doi:10.1371/journal.pone.0027616.g001
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various extracellular stimuli such as stress and cytokines [29]. In
cancer cells, NFkB is often activated aberrantly, promoting the
invasion, metastasis, and survival of these cells. Indeed, NFkB
overexpression is associated with poor prognosis in various
malignancies including MIBC [30] and with CRT resistance in
esophageal cancer [13,14]. The current study showed that NFkB
overexpression is closely related to CRT resistance in MIBC and
that, in cooperation with erbB2 overexpression, it potentially
affects the prognoses of MIBC patients treated with induction
CRT and cystectomy. These results strengthen the case for a
putative role of NFkB inhibitors, of which many types are under
clinical investigation [29], in overcoming CRT resistance in MIBC
overexpressing NFkB.
The current study indicates that both erbB2 and NFkB are
putative targets for treatments to overcome CRT resistance in
MIBC. Among the small molecules currently being investigated in
clinical studies, heat shock protein 90 (Hsp90) inhibitors can
simultaneously block the activity of both of these oncoproteins
[31]. Hsp90 is a ubiquitous molecular chaperone required for the
stability and function of numerous client proteins, including a
number of oncoproteins essential for the acquisition and
maintenance of cancer hallmarks [31,32,33]. Hsp90 inhibitors
destabilize Hsp90 clients by dissociating Hsp90-Hsp90 client
complexes and thereby exerting antitumor activity [34]. Since
both erbB2 and inhibitor of kB kinase b (IKKb), which mediates
NFkB activation, are Hsp90 client proteins [31], adjunctive use of
Hsp90 inhibitors is expected to efficiently sensitize MIBCs
overexpressing erbB2 and/or NFkB to CRT. Indeed, we have
confirmed that low-dose Hsp90 inhibitors effectually potentiate the
effects of CRT on bladder cancer cells overexpressing erbB2 and
NFkB in preclinical models [35].
Table 2. Risk factors predicting CRT resistance.
Variables Univariate Multivariate
CRT resistance
rate (%) P value RR P value
Gender 0.28 0.062
Female 80.0 7.79
Male 60.0 1
Age 0.17
,71 81.3
$71 57.9
Clinical T stage 0.28
T2 57.1
T3-4a 76.2
Tumor size 0.075
,5 cm 52.9
$5 cm 83.3
Multifocality 0.71
No 75.0
Yes 65.2
Presence of CIS 1.00
No 67.9
Yes 71.4
Presence of hydronephrosis 0.056 0.038
No 56.5 1
Yes 91.7 14.3
ErbB2 0.003 0.014
Negative (,20%) 46.7 1
Positive ($20%) 85.0 11.8
NFkB 0.055 0.024
Negative (,20%) 56.5 1
Positive ($20%) 91.7 15.4
p53 0.45
Negative (,10%) 80.0
Positive ($10%) 64.0
Survivin 1.00
Negative (,20%) 71.4
Positive ($20%) 67.9
Combination of erbB2
and NFkB
,0.0001 -
Dual negative 11.1
Single or dual positive 88.5
RR, relative risk.
doi:10.1371/journal.pone.0027616.t002
Table 3. Risk factors predicting bladder cancer death.
Univariate Multivariate
Variables HR P value HR P value
Gender 0.94
Female vs Male 1.05
Age 0.80
,71 vs $71 1.18
Clinical T stage 0.057
T3-4a vs 2 3.91
Tumor size 0.37
$5c mv s,5 cm 1.78
Multifocality 0.20
Yes vs No 2.54
Presence of CIS 0.32
Yes vs No 0.40
Presence of hydronephrosis 0.008 0.018
Yes vs No 5.71 5.56
ErbB2 0.97
Positive vs Negative 1.03
NFkB 0.24
Positive vs Negative 2.13
Combination of erbB2 and
NFkB
0.19 0.056
Single or dual positive
vs dual negative
3.26 21.5
p53 0.53
Positive vs Negative 0.64
Survivin 0.30
Positive vs Negative 0.46
CRT resistance 0.003 0.003
Yes vs No 6.9610
7 5.2610
6
HR, hazard ratio.
doi:10.1371/journal.pone.0027616.t003
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induction CRT is a prerequisite for bladder preservation; patients
with residual disease are at higher risk for bladder cancer death
despite undergoing salvage radical cystectomy [4,7,26]. This is the
reason why CRT resistance was stringently defined as pathological
non-CR in the current study. When CRT resistance was instead
defined as the presence of disease at pathological stage T2 or
greater remaining in a cystectomy specimen, overexpression of
survivin (with a cut-off value of 40%) was also identified as an
independent predictor of CRT resistance. Survivin, a member of
the inhibitor of apoptosis protein family, is reportedly associated
with local failure in high-grade T1 bladder cancer patients treated
with CRT [19]. Recently, a small molecule inhibiting survivin has
been identified and is now in clinical trials [36]. This compound is
also expected to sensitize MIBC to CRT in clinical settings.
The current study has some limitations including a small cohort
size, selection bias, and its retrospective nature. To precisely assess
CRT sensitivity in cystectomy specimens from patients who had
visible tumors before CRT, only 35 out of 162 patients were
eligible for analysis. The fact that statistically significant results
were obtained despite such a small number of subjects might be
attributed to the stringent selection of subjects for analysis. A
prospective study in a larger cohort is needed to validate the
findings obtained in the current retrospective study.
In conclusion, erbB2 and NFkB overexpression are relevant to
CRT resistance of MIBC, and overexpression of at least one of
these oncoproteins potentially increases the risk for cancer death in
MIBC patients treated with induction CRT and cystectomy.
ErbB2 and NFkB are potential targets for treatment to overcome
CRT resistance of MIBC.
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